Li, PingWalsh, Julia R.Lopez, KevinIsidan, AbdulkadirZhang, WenjunChen, Angela M.Goggins, William C.Higgins, Nancy G.Liu, JianyunBrutkiewicz, Randy R.Smith, Lester J.Hara, HidetakaCooper, David K.C.Ekser, Burcin2022-12-142022-12-142021-06-23Li P, Walsh JR, Lopez K, et al. Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses [published correction appears in Sci Rep. 2021 Aug 16;11(1):16967]. Sci Rep. 2021;11(1):13131. Published 2021 Jun 23. doi:10.1038/s41598-021-92543-yhttps://hdl.handle.net/1805/30727Xenotransplantation (cross-species transplantation) using genetically-engineered pig organs offers a potential solution to address persistent organ shortage. Current evaluation of porcine genetic modifications is to monitor the nonhuman primate immune response and survival after pig organ xenotransplantation. This measure is an essential step before clinical xenotransplantation trials, but it is time-consuming, costly, and inefficient with many variables. We developed an efficient approach to quickly examine human-to-pig xeno-immune responses in vitro. A porcine endothelial cell was characterized and immortalized for genetic modification. Five genes including GGTA1, CMAH, β4galNT2, SLA-I α chain, and β2-microglobulin that are responsible for the production of major xenoantigens (αGal, Neu5Gc, Sda, and SLA-I) were sequentially disrupted in immortalized porcine endothelial cells using CRISPR/Cas9 technology. The elimination of αGal, Neu5Gc, Sda, and SLA-I dramatically reduced the antigenicity of the porcine cells, though the cells still retained their ability to provoke human natural killer cell activation. In summary, evaluation of human immune responses to genetically modified porcine cells in vitro provides an efficient method to identify ideal combinations of genetic modifications for improving pig-to-human compatibility, which should accelerate the application of xenotransplantation to humans.en-USAttribution 4.0 InternationalInnate immune cellsTransplant immunologyGenetic engineeringArticle